TY - JOUR
T1 - The role of radiation therapy in the treatment of metastatic cancer
AU - Stea, Baldassarre
AU - Skrepnik, Tijana
AU - Hsu, Charles C.
AU - Abendroth, Roy
N1 - Publisher Copyright: © 2018, Springer Nature B.V.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Radiation therapy continues to play an important role in the management of cancer. In this review, we discuss the use of radiation therapy to target and control micrometastatic disease (adjuvant use of radiation), or using stereotactic radiation therapy to address small volumes of gross disease, such as oligometastases, and finally the use of radiation therapy in the era of immunotherapy. Radiation therapy is commonly used to treat nodal basins suspected of harboring microscopic disease. More recently, computer and technical innovations have allowed radiation oncologists to treat small volumes of gross disease within the brain and also in the body with great success, adding to the cancer armamentarium. This modality of cancer treatment that began shortly after the discovery of X-rays by William Roentgen continues to evolve and finds new clinical applications which minimize toxicity while increasing effectiveness. The newly discovered interactions of high dose/fraction radiation (stereotactic radiosurgery) with immune check point inhibitors in melanoma is the latest example of how synergism can be achieved between two different modalities thus increasing the therapeutic ratio to control metastatic cancer.
AB - Radiation therapy continues to play an important role in the management of cancer. In this review, we discuss the use of radiation therapy to target and control micrometastatic disease (adjuvant use of radiation), or using stereotactic radiation therapy to address small volumes of gross disease, such as oligometastases, and finally the use of radiation therapy in the era of immunotherapy. Radiation therapy is commonly used to treat nodal basins suspected of harboring microscopic disease. More recently, computer and technical innovations have allowed radiation oncologists to treat small volumes of gross disease within the brain and also in the body with great success, adding to the cancer armamentarium. This modality of cancer treatment that began shortly after the discovery of X-rays by William Roentgen continues to evolve and finds new clinical applications which minimize toxicity while increasing effectiveness. The newly discovered interactions of high dose/fraction radiation (stereotactic radiosurgery) with immune check point inhibitors in melanoma is the latest example of how synergism can be achieved between two different modalities thus increasing the therapeutic ratio to control metastatic cancer.
KW - Adjuvant radiation
KW - Immune checkpoint inhibitors
KW - Oligometastatic disease
KW - Stereotactic radiosurgery
KW - Synergism of stereotactic radiosurgery
UR - http://www.scopus.com/inward/record.url?scp=85050982532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050982532&partnerID=8YFLogxK
U2 - 10.1007/s10585-018-9926-6
DO - 10.1007/s10585-018-9926-6
M3 - Review article
C2 - 30062507
SN - 0262-0898
VL - 35
SP - 535
EP - 546
JO - Clinical and Experimental Metastasis
JF - Clinical and Experimental Metastasis
IS - 5-6
ER -